Highlights

  • 4DMedical reported AUD 7.1 million FY26 revenue, increasing 21% year on year.
  • Q1 FY27 scan volumes reached 119,672, rising 61% from a year earlier.
  • Its software install base expanded to 724 sites globally by September 2026.
  • The September quarter closed with AUD 242.8 million in cash.

4DMedical Ltd (ASX:4DX) develops respiratory imaging software that analyses conventional medical scans to provide information on lung structure and function. During 2026, the company expanded clinical deployments and partnerships while reporting a larger scan-processing footprint.

Scan Activity Expands Across a Larger Network

For the September 2026 quarter, the first quarter of FY27, 4DMedical (ASX:4DX) processed 119,672 scans, 61% more than in the prior corresponding period. Software products were delivered at 724 sites worldwide, representing growth of 77% year on year and 34% from June 2026.

In the United States, SimonMed completed the rollout of CT:VQ and LDAf across 125 CT-enabled sites and entered another three-year agreement for IQ-UIP lung fibrosis analysis. Stanford Medicine also renewed its software agreement for 12 months through July 2027, including a minimum allocation of CT:VQ scans.

Clinical Agreements Add Different Revenue Channels

A major US Veterans Affairs healthcare network selected the company’s LDAi software for chronic obstructive pulmonary disease detection. The arrangement is described as a five-year agreement comprising an initial one-year term and annual extensions. Management expects approximately USD 800,000 in revenue over the full term; that amount is an expectation, not revenue already recognised. Separately, the company reported new Australian CT:VQ agreements involving Jones Radiology, Qscan and providers in the Integral Diagnostics network.

European activity includes a contextflow lung cancer screening deployment with Curagita covering approximately 25,000 procedures at 25 German locations over three years. A pharmaceutical analytics agreement with GSK announced in April provides another route to commercial activity through clinical research rather than routine hospital scans. 4DMedical (ASX:4DX) has not disclosed the GSK agreement’s value, limiting assessment of its individual revenue contribution.

Revenue Growth and Cash Resources

Operating revenue for FY26 rose 21% to AUD 7.1 million, with reported gross margins above 90%. Unaudited Q1 FY27 Operating Revenue increased 66% year on year to AUD 2.3 million, again with gross margins above 90%. They should also be considered separately from installation counts, which do not establish the level of recurring billings at each site.

At 30 September 2026, 4DMedical (ASX:4DX) held AUD 242.8 million in cash. The balance provides financial resources for clinical studies, customer implementation and operating expenditure, although it does not establish when operations might become cash-flow positive. The FY26 Annual Report also disclosed substantial statutory losses affected by non-cash financial instrument remeasurement, underscoring the need to distinguish reported accounting outcomes from ongoing commercial performance.

Clinical Evidence and Execution Priorities

The CLEAR clinical evidence programme is studying CT:VQ in acute pulmonary embolism assessment. Recruitment and site activation were reported to be progressing to plan in October, with a study readout expected in calendar 2027. A proposed US legislative pilot for four-dimensional lung imaging is likewise not an enacted programme and should not be counted as an existing commercial contract.

For 4DMedical (ASX:4DX), near-term developments to monitor include additional scan utilisation at deployed sites, renewal and expansion of customer agreements, reimbursement arrangements and delivery of clinical evidence.

Key Insights

4DMedical’s 2026 disclosures show a larger clinical footprint and higher operating revenue, supported by US customer renewals, network deployments and European contracts. Its AUD 242.8 million cash balance offers capacity to continue commercialisation and research. Nevertheless, the timing of expected contract revenue, ongoing cash requirements and the pending CLEAR study findings remain relevant uncertainties when assessing the next reporting periods.